Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. - Wikidata - awgldk - TriplyDB

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.

http://www.wikidata.org/entity/Q45201798

about

Modulation of T-cell activation by malignant melanoma initiating cells Stem cells and targeted approaches to melanoma cure Melanoma Risk and Survival among Organ Transplant Recipients.Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?Melanoma: tumor microenvironment and new treatments.Immunological network signatures of cancer progression and survival Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.Highly clonal regulatory T-cell population in follicular lymphoma - inverse correlation with the diversity of CD8(+) T cells.Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases Immune correlates of melanoma survival in adoptive cell therapy.Characterization of the melanoma brain metastatic niche in mice and humans.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines Expression of leukotriene B₄ receptor-1 on CD8⁺ T cells is required for their migration into tumors to elicit effective antitumor immunity.Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma.Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma.Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival.Lessons from cancer immunoediting in cutaneous melanoma.The tumor microenvironment: a pitch for multiple players.Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery?Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.Mycobacterium bovis Bacillus Calmette-Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function.Surgical outcomes in patients with cutaneous malignant melanoma in Europe - a systematic literature review.Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors.Antitumor immunity and cancer stem cells Human Tumor Antigens and Cancer Immunotherapy.Intratumoral and Peritumoral Mast Cells in Malignant Melanoma: An Immunohistochemical Study.Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Ca Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients.Integrative clinical genomics of metastatic cancer.Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America.Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.Upregulation of granzyme B and interferon-γ mRNA in responding lesions by treatment with nivolumab for metastatic melanoma: a case report.

P2860

Q24595394-8506CE47-835F-4B4B-A6D3-D0F945409013 Q26825014-92CCC184-AA6D-4E3A-947A-94E41B53C8B7 Q27320787-092DDD44-FA9B-4DDD-956A-BD9D0DC121D5 Q28607232-472FB1C2-5721-447E-B4C2-00BD64BA1659 Q29994573-177B8E2A-2766-4D8F-8378-72B40F6152A8 Q33675676-BCB69F49-B256-4599-98AD-B091FA2A530F Q33858844-42CC18BE-6CD9-4838-B16F-E4CC5238D384 Q35543740-85F65797-10B6-4F27-8745-7A124AB83153 Q35798858-600B47DC-3C57-4712-BC66-AF8D779AFF93 Q36562180-35239997-1A20-4AAF-A591-206CC4E5794B Q36694896-7DE308A6-683C-419C-ADD0-F73ACA8AA7C2 Q36804855-D19EEB1C-626A-4E82-B24E-AB9E5300D708 Q37137360-D50D9A38-665A-47F0-AB78-B1FDFABFD0E6 Q37274068-43C15006-02E4-4C7D-8899-02C8C15325DA Q37289626-F03FFB23-4658-4645-8E6A-0CE1281D9CF1 Q37514024-1E07C793-B38F-4194-9077-AAD845AEA8F3 Q37718449-D263B73F-4272-4932-B7C0-99E26C82E2E4 Q37741565-9D291BCA-5AFD-4680-AF5D-3E71211D4851 Q38038176-399F3622-A0D6-4B38-B6D2-A660B4FEA8B0 Q38101567-4145E91D-CED6-4533-AE25-5B7AAB8243E2 Q38106658-43BE2CA3-E23E-4CE7-BE96-1A815CAB06D6 Q38394496-679FD713-0D2E-45AA-851A-BC9F1AA82959 Q38604832-F7A79EA2-D10C-4A19-ADD0-35C9C88B1C79 Q38942422-91BF8895-93F3-44D3-A4A4-61F811CBE47D Q39187442-45280AC1-FB25-4C77-B36E-88295CE0BF7F Q41483538-CB02886C-16B3-456C-BE8D-437FE8DE0CEA Q41520738-E071F35F-2649-40E5-9E31-1A04AF422D6C Q41533232-921CA3EB-157E-4F5C-A5A6-EA5BDA1A5DAA Q42010315-17DDC4A7-3C7C-432F-9D4E-31584342A201 Q42112527-D36117A8-2431-41F5-AC99-47D8F821472A Q42511387-E592D856-562F-47A0-9A45-9EBAB30B82E3 Q46540302-E24904EB-7C6C-4D5F-B04B-279EFC6DE99D Q47350013-CF235ED9-D813-4DA4-A3DE-A101DA839091 Q48252817-69DBC509-C030-4BBB-A001-2C6AB4BC6739 Q48267403-F20F3FB5-139D-4960-831B-7E89DBCFE1FC Q48333472-09CDDD9C-1277-4C05-87A3-95D847F0CFEE Q53068034-0C8082FA-0292-4F71-91FD-88886F71CA53 Q53186991-7800B70E-9697-432A-ACE2-37AD1273E6C9

P2860

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.

http://www.wikidata.org/entity/Q45201798

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Favorable outcome in clinicall ...... HC class I antigen expression.

@en

Favorable outcome in clinicall ...... HC class I antigen expression.

@nl

type

label

Favorable outcome in clinicall ...... HC class I antigen expression.

@en

Favorable outcome in clinicall ...... HC class I antigen expression.

@nl

prefLabel

Favorable outcome in clinicall ...... HC class I antigen expression.

@en

Favorable outcome in clinicall ...... HC class I antigen expression.

@nl

P1433

Q45201798-ECACC4E1-21E5-4BB4-B002-B30C522FE2C9

P1476

Q45201798-FF537C1E-3784-48E1-81DF-707E2EE811CA

P2093

Q45201798-05775C74-3062-4F48-9537-253E9B54ADB6

Q45201798-2C291651-4F1B-47CF-9CC0-DB9EEAB625DD

Q45201798-3A38A7AE-7AC5-42CA-B740-A64A3D995F2C

Q45201798-491844F3-C46F-4D5D-BFDB-B640DFE0E0E0

Q45201798-4E294B4C-BF02-4B06-BA48-EDA01ED60633

Q45201798-50A91552-DF9B-404A-85EF-754841E8EFA5

Q45201798-83F11FB7-6A5C-4D17-9E58-EDDA44078CFF

Q45201798-B9686757-8DCD-49C6-A156-9187CF21A2FE

Q45201798-BCCB24E4-3A2C-4A29-8793-AFA793BF989C

Q45201798-D0C44274-E006-485A-ABA2-1B434ECEA009

P2860

Q45201798-0150FF35-C9B0-4296-A039-92C31535B10F

Q45201798-0699BE08-ED6D-416B-8122-29FA168ED1DA

Q45201798-09EF58C8-E3B6-406B-A4F0-8F30531F7DEE

Q45201798-0A8DBFAE-0F62-4C0D-A9E8-C051C9C2D506

Q45201798-188D221B-7098-4AB8-A308-4F01981528D6

Q45201798-1E7179C8-C3FB-46CE-8A60-1ACA83537DCD

Q45201798-2DFE2CBC-BB62-4D12-8A00-48C00BD5CF0B

Q45201798-325B29B3-9CBE-41DA-A283-9E5D1B650FB4

Q45201798-3498D1F8-E81B-4081-8ED5-B8B70F6439F9

Q45201798-35855494-7097-497A-BBFD-AE84FBA0C6A4

P304

Q45201798-C7E8DF85-5A52-428D-8CD7-165775F8807F

P31

Q45201798-739F85AE-DF00-4018-9E7B-D4A3AE23E9F0

P356

Q45201798-EE19F313-2156-4F36-BC3D-E3180E4CBA06

P433

Q45201798-20BECE67-22AE-4AE7-9A19-60EC0A0251C3

P478

Q45201798-39876A51-1304-4ED5-9A3B-C4433C8F6384

P577

Q45201798-B4AB22CF-A126-4E51-91EA-882DDAFE8B34

P5875

Q45201798-B8149204-03A6-4A7B-A40D-E7CA865F6139

P698

Q45201798-1E33368B-3512-481F-B041-8989FA52A8DF

P921

Q45201798-30CC8433-DDE2-42AB-8EF2-45439957B045

P356

P1433

International Journal of Cancer

P1476

Favorable outcome in clinicall ...... HC class I antigen expression.

@en

P2093

Alfons J M van den Eertwegh

http://www.w3.org/2001/XMLSchema#string

Barbara G Molenkamp

http://www.w3.org/2001/XMLSchema#string

Berbel J R Sluijter

http://www.w3.org/2001/XMLSchema#string

Chris J L M Meijer

http://www.w3.org/2001/XMLSchema#string

Erik Hooijberg

http://www.w3.org/2001/XMLSchema#string

Inge S van Houdt

http://www.w3.org/2001/XMLSchema#string

Joost J Oudejans

http://www.w3.org/2001/XMLSchema#string

Laura M Moesbergen

http://www.w3.org/2001/XMLSchema#string

Paul A M van Leeuwen

http://www.w3.org/2001/XMLSchema#string

Tanja D de Gruijl

http://www.w3.org/2001/XMLSchema#string

P2860

Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma

The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites

Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma

Presentation of antigens by MHC class II molecules: getting the most out of them

Selective MHC expression in tumours modulates adaptive and innate antitumour responses.

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

The epidemiology of skin cancer.

Transcriptional regulation of antigen presentation.

Helper T cells, dendritic cells and CTL Immunity.

Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression

P304

609-615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.23543

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5352288

http://www.w3.org/2001/XMLSchema#string

P698

18498132

http://www.w3.org/2001/XMLSchema#string

P921